Patient eligibility

Treatment with biological agents can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 and Section 100 for adult patients with severe Crohn’s disease.

Where the term biological agent appears it refers to adalimumab, infliximab, ustekinumab and vedolizumab.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

Initial grandfather treatment

For patients who received non-PBS subsidised vedolizumab treatment before 1 August 2015 or ustekinumab treatment before 1 September 2017 for severe Crohn’s disease, make all initial grandfather applications in writing and: